

Home

4401 Rosedale Ave  
Bethesda, MD 20814  
Tel: (301) 986-1989  
Cell: (443) 864-6287

July, 2003

---

## EDUCATION

Ph.D., Organic Chemistry (1980) - University of Grenoble, France  
M.S., Biochemistry (1976) - University of Lyon, France

## SUMMARY

Scientific background includes over 25 years of experience in basic academic and industrial research and vaccinology, encompassing the rationale design, development and testing of a broad bacterial glycoconjugate vaccine platform and diagnostics for human diseases attributable to *Streptococcus agalactiae*, *Neisseria meningitidis*, *Haemophilus influenzae*, *Streptococcus pyogenes*, *Streptococcus pneumoniae*, and *Staphylococcus aureus*. Earlier work (1983- 1991) at the National Research Council of Canada in Ottawa focused on the structure, conformation, immunobiology, and role in pathogenesis of capsular polysaccharides of important human pathogenic bacteria and the development of semi-synthetic vaccines against disease caused by these bacteria. More recent work at Baxter / North American Vaccine (1992 - 2003) has consisted of rationale design, preparation, preclinical studies, and technology transfer for more than a dozen human vaccines which have included all the major serogroups/types for meningococcal, streptococcal, pneumococcal, and Hib polysaccharide conjugates; rPA Anthrax, rOspA Lyme and various combinations. These studies resulted in a licensed product (NeisVac-C™), as well as numerous publications, patents, world-wide regulatory filings, and achievement awards, including the Baxter Distinguished Corporate Contribution Award in 2001 for the development and licensure of its meningococcal C conjugate vaccine, NeisVac-C™ with sales of over \$150 million. Recent management responsibilities as Senior Director of Research for Baxter BioScience-included the following vaccine research departments: Carbohydrate Chemistry, Immunology, Microbiology, Molecular Biology, and Protein Chemistry.

## EXPERIENCE

BAXTER HEALTHCARE CORPORATION, BIOSCIENCE, COLUMBIA, MD: JUNE, 2000 – PRESENT  
NORTH AMERICAN VACCINE, INC. (ACQUIRED BY BAXTER), COLUMBIA, MD: NOVEMBER, 1992 – JUNE, 2000

*Senior Director, Research (December, 2002 – present) – Baxter*

- Responsible for management of 5 vaccine research departments (20 people) including: Carbohydrate Chemistry, Microbiology, Immunology, Molecular Biology, and Protein Chemistry.
- Direct rationale design, preparation, formulation and preclinical studies of polysaccharide conjugates, recombinant, and combination vaccines to cover groups A/B/C/Y/W135 meningococci, groups A & B streptococci, pneumococci, and Hib.
- Direct upstream and downstream technology transfer from Research to Process Development, Clinical Manufacturing, and Quality Control.
- Served as sponsor for meningococcal C/Y/W135 combination conjugate vaccine delivering first Phase I clinical lots.

- Liaison between Research and other functional areas, including Project Management, Process Development, Quality, Regulatory, Clinical, Legal, Finance, Safety, and Human Resources.
- Sponsor for meningococcal conjugate vaccines.
- Recipient of 5 Baxter technical awards, including Baxter Distinguished Corporate Contribution award for development and licensure of meningococcal C conjugate vaccine with sales of over \$150 million.
- Plan and manage departmental program resources.
- Plan research strategies, evaluate new technologies, and set up outside collaborations.

***Director, Research / Senior Director, Carbohydrate Chemistry (June, 2000 – December, 2002) – Baxter***  
***Senior Director, Carbohydrate Chemistry (November, 1992 – June, 2000) – NAVA***

- Responsible for management of the Carbohydrate Chemistry research department (11 people).
- Worked through due diligence conducted on NAVA, providing numerous vaccine presentations leading to \$400 million acquisition by Baxter.
- Directed preparation, formulation and preclinical studies on conjugate and combination vaccines to cover meningococci, groups A & B streptococci, pneumococci, and Hib.
- Served as sponsor for meningococcal B, Hib, and streptococcal B conjugate vaccines delivering first Phase I clinical lots.
- Planned and managed departmental program resources.
- Planned research strategies, evaluate new technologies, and set up outside collaborations.

***Director, Carbohydrate Chemistry (November, 1992 – August, 1999) - NAVA***

- Responsible for management of the Carbohydrate Chemistry department (11 people).
- Directed conceptuel design, preparation, formulation and preclinical studies on conjugate and combination vaccines to cover meningococci, groups A & B streptococci, pneumococci, and Hib.
- Member of joint management team, and liaison in NAVA/Pasteur Mérieux Connaught partnership on meningococcal B conjugate vaccine.
- Planned and managed departmental program resources.
- Planned research strategies, evaluate new technologies, and set up outside collaborations.

***Senior Scientist and Group Leader (September, 1987 - November, 1992) – Biochem Pharma***

- Initiated Development of Conjugate technology platform at the NRC in Ottawa, Canada.
- Rationale design of meningococcal C conjugate vaccine (NeisVac-C), streptococcal B and pneumococcal conjugates.
- Established basic IP portfolio of patents.
- ConjugateTechnology transfer to NAVA.

## **AWARDS**

**Award from the National Research Council of Canada (2001) for the Generation of Substantial Royalties for the Meningococcal C Vaccine**

**Baxter Distinguished Corporate Contribution (2001): De-O-Acetylated Protective Epitope on the MenC Polysaccharide – A Novel Conjugate Vaccine against Meningococcal C Meningitis.**

**Baxter Outstanding Innovation (2001): Development of Novel Carrier Proteins / Group B Meningococcal Vaccine Conjugate Vaccine.**

**Baxter Outstanding Innovation (2001): Novel Semi-Synthetic Polysaccharide-Protein Conjugate Vaccines.**

**Baxter Special Accomplishment (2001): Development of a Novel *Haemophilus Influenzae* Polysaccharide Conjugate Vaccine.**

**Baxter Special Accomplishment (2001): Polysaccharide Purification Technology Platform.**

## **PATENTS**

- US5,225,331** Immunoassay for detecting group B streptococcus (1993)
- US5,425,946** Vaccines against group C Neisseria meningitidis (1995)
- US5,576,002** Meningococcal polysaccharide conjugate vaccine (1996)
- US5,683,699** Meningococcal polysaccharide conjugate vaccine (1997)
- US5,773,007** Vaccine compositions (1998)
- US5,811,102** Modified meningococcal polysaccharide conjugate vaccine (1998)
- US5,866,135** Group A streptococcal polysaccharide conjugate vaccine (1999)
- US5,902,586** Meningococcal polysaccharide conjugate vaccine (1999)
- US5,969,130** Meningococcal polysaccharide conjugate vaccine (1999)
- US6,248,570** Procedure for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to protein as conjugate vaccines (2001)
- US6,267,961** Direct methods for molar-mass determination of fragments of Haemophilus influenzae type b capsular polysaccharides and vaccine preparations (2001)
- US6,284,884** Antigenic group B streptococcus type II and III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof (2001)
- US6,350,449** Antibodies to meningococcal polysaccharide conjugate vaccines (2002)
- US6,372,222** Antigenic group B streptococcus type II and III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof (2002)
- US6,451,317** Immunogenic conjugates comprising a Group B meningococcal porin and an Haemophilus influenzae polysaccharide (2002)
- US6,596,283**..Meningococcal polysaccharide conjugate vaccines (2003).
- US6,602,508** Method of Immunization using a Group B Streptococcus type II and Type III polysaccharide conjugate vaccine

## **World PCT Publications**

- WO9108772A1** Improved meningococcal polysaccharide conjugate vaccine (1991)

**WO9204915A1** Improved vaccine compositions (1992)

**WO9219969A1** Immunoassay for detecting group B streptococcus (1992)

**WO9528960A1** Group A streptococcal polysaccharide immunogenic compositions and methods (1995)

**WO9640239A1** Modified meningococcal polysaccharide conjugate vaccines (1996)

**WO9640795A1** Antigenic group B streptococcus type II and III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof (1996)

**WO9728273A1** Expression of Group B Neisseria meningitidis outer membrane (MB3) protein from yeast and vaccines

**WO9822490A1** Direct methods for molar-mass determination of fragments of Haemophilus influenzae type b capsular polysaccharides vaccine preparations (1998)

**WO9903501A1** Immunogenic conjugates comprising a Group B meningococcal porin and an Haemophilus influenzae polysaccharide (1999)

**WO9903884A2** Modified immunogenic pneumolysin compositions as vaccines (1999)

**WO9932653A1** Procedure for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugate vaccines (1999)

**WO0010599A2** Immunogenic  $\beta$ -Propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an N-acryloylated polysaccharide (2000)

**WO02092131A2** Immunogenic compositions of low molecular weight hyaluronic acid and methods to prevent, treat and diagnose infections and diseases caused by group A and C streptococci (2002)

**WO02092131A3** Immunogenic conjugates of low molecular weight hyaluronic acid with polypeptide toxins (2002)

#### **PROVISIONAL PATENT APPLICATIONS**

**No. 20695/0014** Chimeric multivalent polysaccharide conjugate vaccines (filed July 30, 2002)

**No. 38777/0050** Carriers proteins for vaccines (filed June 23, 2003)

**No. 38777/0055** Meningococcal Y conjugate vaccines and combinations thereof (filed June 23, 2003)

## PUBLICATIONS IN PEER REVIEW JOURNALS WITH INTERNATIONAL CIRCULATION

1. JOSELEAU, J.P., Michon, F. and Vignon, M. Structural investigations on the capsular polysaccharide from *Klebsiella* serotype K-34 and its characterization by NMR spectroscopy. **CARBOHYDRATE RESEARCH** 101, 175-185, 1982.
2. Banoub, J.H. and Michon, F. Chromium trioxide oxidation of acetylated 3-amino-3,6-dideoxy-L-hexosides. **CANADIAN JOURNAL OF BIOCHEMISTRY** 60, 517-520, 1982.
3. Banoub, J.H. and Michon, F. A rapid GLC-MS method for identification of the N-acetyl group of amino sugars in complex carbohydrates. **CARBOHYDRATE RESEARCH** 100, C24-C26, 1982.
4. Vignon, M., Michon, F., Joseleau, J.P. and Bock, K. Molecular motion of branched chain polysaccharides studied by  $^{13}\text{C}$ -NMR spin-lattice relaxation rates. **MACROMOLECULES** 16, 835-838, 1983.
5. Banoub, J.H., Michon, F. Rice, J. and Rateb, L. Kinetic studies on the rearrangement of 3,4-di-O-benzyl-1,2-O-(1-methoxy-ethylidene)-L-rhamnopyranoside with a catalytic amount of 1,1,3,3-tetramethylurea-trifluoromethane sulfonic acid at different temperatures. **CARBOHYDRATE RESEARCH** 123, 109-116, 1983.
6. Banoub, J.H., Choy, Y.M., Michon, F. and Shaw, D.H. Structural investigation on the core oligosaccharide of *Aeromonas hydrophila* Chemotype II. **CARBOHYDRATE RESEARCH** 114, 267-276, 1983.
7. Banoub, J.H., Shaw, D.H. and Michon, F. Hydrolytic release and identification by Glc-MS of 3-deoxy-D-manno-2-octulosonic acid in the lipopolysaccharides isolated from bacteria of the Vibrionaceae. **CARBOHYDRATE RESEARCH** 123, 117-122, 1983.
8. Banoub, J.H., Michon, F., Shaw, D.H. and Roy, R. EI and CI mass spectral identification of some derivatives of 7-O-[2-amino-2-deoxy-D-glucopyranosyl]-L-glycero-D-mannoheptose, obtained from lipopolysaccharides representative of the *Vibrionaceae* family. **CARBOHYDRATE RESEARCH** 128, 203-216, 1984.
9. Michon, F., Roy, R., Jennings, H.J. and Ashton, F.E. Structural elucidation of the capsular polysaccharide of *Neisseria meningitidis* Group H. **CANADIAN JOURNAL OF CHEMISTRY** 62, 1519-1524, 1984.
10. Michon, F., Shaw, D.L. and Banoub, J.H. Structure of the lipopolysaccharide core isolated from a human strain of *Aeromonas hydrophila*. **EUROPEAN JOURNAL OF BIOCHEMISTRY** 145, 107-114, 1984.
11. Jennings, H.J., Katzenellenbogen, E., Lugowski, C., Michon, F., Roy, R. and Kasper, D.L. Structure, conformation and immunology of sialic acid-containing polysaccharides of human pathogenic bacteria. **PURE AND APPLIED CHEMISTRY** 56, 893-905, 1984.
12. Banoub, J.H., Michon, F. and Shaw, D.H. Formation of 1,6-anhydro-3,4-di-O-acetyl-2,7-di-O-methyl-L-glycero-D-manno-heptopyranose during methylation analysis of lipopolysaccharide-cores representative of the *Vibrionaceae* family. **CARBOHYDRATE RESEARCH** 138, 171-175, 1985.

13. Jennings, H.J., Roy, R. and Michon, F. Determinant specificities of the Groups B and C of *Neisseria meningitidis* polysaccharides. **JOURNAL OF IMMUNOLOGY** 134, 2651-2657, 1985.
14. Jennings, H.J., Roy, R. and Michon, F. Conformational determinant critical to the immunospecificity of the Group B *Neisseria meningitidis* polysaccharide. **FEDERATION PROCEEDINGS** 44, 779, 1985.
15. Banoub, J.H., Michon, F., Roy, R., Grouiller, A. and Bazin, H. EI and CI mass spectroscopy of peracetylated methyl glycosides and alditols of 2-amino-2,4-dideoxy-DL- and 3-amino-3,4-dideoxy-DL-pentopyranoses. **CARBOHYDRATE RESEARCH** 144, 127-136, 1985.
16. Michon, F., Brisson, J-R., Roy, R., Ashton, F.E. and Jennings, H.J. Structure of the capsular polysaccharide of *Neisseria meningitidis* Group I. A 2D-NMR analysis. **BIOCHEMISTRY** 24, 5592-5598, 1985.
17. Michon, F., Brisson, J-R., Roy, R., Ashton, F.E. and Jennings, H.J. Structure of the capsular polysaccharide of *Neisseria meningitidis* Group K. A 2D-NMR analysis. **CANADIAN JOURNAL OF CHEMISTRY** 63, 2781-2786, 1985.
18. Banoub, J.H., Michon, F. and Cooper, F. Occurrence of 3-acetamido-3,6-dideoxy-4-O-methyl-L-glucose in the O-polysaccharide of *Vibrio anguillarum*. **CANADIAN JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY** 63, 1265-1267, 1985.
19. Banoub, J.H., Michon, F. and Hodder, H.J. Structural elucidation of the O-specific polysaccharide of the phenol-phase soluble lipopolysaccharide of *Vibrio anguillarum*. **CANADIAN JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY** 65, 19-26, 1986.
20. Michon, F., Katzenellenbogen, E., Jennings, H.J. and Kasper, D.L. Structure of the complex group specific polysaccharide of *Group B Streptococcus*. **BIOCHEMISTRY** 26, 476-486, 1987.
21. Lee, J.C., Michon, F., Perez, N.E., Hopkins, C.A. and Pier, G.B. Chemical characterization and immunogenicity of capsular polysaccharide isolated from mucoid *Staphylococcus aureus*. **INFECTION AND IMMUNITY** 55, 2191-2197, 1987.
22. Michon, F., Brisson, J-R. and Jennings, H.J. Conformational differences between linear -(2,8)-linked homosialo-oligosaccharides and the epitope of the Group B meningococcal polysaccharide. **BIOCHEMISTRY** 26, 8399-8045, 1987.
23. Jennings, H.J., Gamian, A., Michon, F., Roy, R. and Ashton, F.E. A chemically modified Group B meningococcal polysaccharide. In *Towards Better Carbohydrate Vaccine* (Bell, R. and Torrigiani, G. eds). John Wiley and Sons Ltd. pp. 11-22, 1987.
24. Jennings, H.J., Ashton, F.E., Gamian, A. Michon, F. and Roy, R. Chemically modified Group B meningococcal polysaccharides as human vaccine. In *Industrial Polysaccharides: Genetic Engineering, Structure/Property Relations and Applications* (Yalpani, M., ed.) pp. 149-156, 1987.
25. Jennings, H.J., Beurret, M., Gamian, A. and Michon, F. Structure and immunochemistry of meningococcal lipopolysaccharides. **ANTONIE VAN LEEUWENHEK JOURNAL OF MICROBIOLOGY** 53, 519-522, 1987.



26. Jennings, H.J., Beurret, M., Gamian, A. and Michon, F. Structure and immunochemistry of meningococcal lipopolysaccharides. In *Gonococci and Meningococci* (Poolman, J.T. et al. eds.), Academic Press, The Netherlands, pp. 553-556, 1988.
27. Michon, F., Brisson, J.-R., Dell, A., Kasper, D.L. and Jennings, H.J. The multiantennary group-specific polysaccharide of *Group B Streptococcus*. *BIOCHEMISTRY* 27, 5341-5351, 1988.
28. Kabat, E.A., Liao, J., Osserman, E.F., Gamian, A., Michon, F. and Jennings, H.J. The epitope associated with the binding of the capsular polysaccharide of the *Group B meningococcus* and of *Escherichia coli* K1 to a human monoclonal macroglobulin, IgM<sup>NOV</sup>. *JOURNAL OF EXPERIMENTAL MEDICINE* 168, 699-711, 1989.
29. Wessels, M.R., Benedi, V.-J., Jennings, H.J., Michon, F., DiFabio, J.L. and Kasper, D.L. Isolation and characterization of the type IV *Group B Streptococcus* capsular polysaccharide. *INFECTION AND IMMUNITY* 57, 1089-1094, 1989.
30. Jennings, H.J., Gamian, A., Michon, F. and Ashton, F.E. Unique intermolecular bactericidal epitope involving the homosialopolysaccharide capsule on the cell surface of *Group B Neisseria meningitidis* and *Escherichia coli* K1. *JOURNAL OF IMMUNOLOGY* 142(10), 3585-3591, 1989.
31. DiFabio, J.L., Michon, F., Brisson, J.-R., Benedi, V.-J., Wessels, M.R., Kasper, D.L. and Jennings, H.J. Structure of the capsular polysaccharide antigen of type IV *Group B Streptococcus*. *CANADIAN JOURNAL OF CHEMISTRY* 67, 877-882, 1989.
32. DiFabio, J.L., Michon, F., Brisson, J.-R., Benedi, V.-J., Wessels, M.R., Kasper, D.L. and Jennings, H.J. Structural determination and immunochemical characterization of the type V *Group B Streptococcus* capsular polysaccharide. *JOURNAL OF BIOLOGICAL CHEMISTRY* 266, 6714-6719, 1991.
33. Michon, F., Pozsgay, V., Brisson, J.-R. and Jennings, H.J. Substrate specificity of naringinase, an -L-rhamnosidase from *Penicillium decumbens*. *CARBOHYDRATE RESEARCH* 194, 321-324, 1989.
34. Ashton, F.E., Michon, F., Ryan, T.A. and Jennings, H.J. Protective efficacy of mouse antiserum to the N-propionylated derivative of the meningococcal Group B polysaccharide. *MICROBIAL PATHOGENESIS* 6, 455-458, 1989.
35. Dell, A., Azadi, P., Tiller, P.R., Thomas-Pates, J.E., Jennings, H.J., Beurret, M. and Michon, F. Analysis of oligosaccharide epitopes of meningococcal lipopolysaccharide by fast atom bombardment mass spectroscopy. *CARBOHYDRATE RESEARCH* 200, 59-76, 1990.
36. Michon, F., Beurret, M., Gamian, A., Brisson, J.-R. and Jennings, H.J. Structure of the L5 lipopolysaccharide-core oligosaccharides epitopes of *Neisseria meningitidis*. *JOURNAL OF BIOLOGICAL CHEMISTRY* 265(13), 7243-7247, 1990.
37. DiFabio, J.L., Michon, F., Brisson, J.-R. and Jennings, H.J. Structure of the L1 and L6 core oligosaccharide epitopes of *Neisseria meningitidis*. *CANADIAN JOURNAL OF CHEMISTRY* 68, 1029-1034, 1990.

38. Paoletti, L.C., Kasper, D.L., Michon, F., DiFabio, J., Holme, K., Jennings, H.J. and Wessels, M.R. An oligosaccharide-tetanus toxoid conjugate vaccine against type III Group B *Streptococcus*. **JOURNAL OF BIOLOGICAL CHEMISTRY** 265, 18278-18283, 1990.
39. Wessels, M.R., Paoletti, L.C., Kasper, D.L., DiFabio, J.L., Michon, F., Holme, K. and Jennings, H.J. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III Group B *Streptococcus*. **JOURNAL OF CLINICAL INVESTIGATION** 86, 1428-1433, 1990.
40. Tzianabos, A., Pantosti, A., Baumann, H., Michon, F., Brisson, J.-R., Jennings, H.J., and Kasper, D.L. Characterization of two surface polysaccharides of *Bacteroides Fragilis*. **TRANS ASSOC AM PHISICIANS** 104, 285-295, 1991.
41. Michon, F., Chalifour, R., Feldman, R., Wessels, M., Kasper, D.L., Gamian, A., Pozsgay, V. and Jennings, H.J. The -L-(1-2)-Trirhamnopyranoside epitope in the group specific polysaccharide of Group B *Streptococcus*. **INFECTION AND IMMUNITY** 59, 1690-1696, 1990.
42. Ashton, F.E., Michon, F., Bundle, D., Gidney, M., Gamian, A. and Jennings, H.J. Immunological properties of monoclonal antibodies to the N-propionyl derivative of Group B meningococcal polysaccharide (Achtman, M., Kohl, P., Marchal, C., Morelli, G., Seiler, A., Thiesen, B., eds.), *Neisseria* 1990. **PROCEEDINGS OF THE SEVENTH INTERNATIONAL PATHOGENIC NEISSERIA CONFERENCE**, Berlin, Germany, September 9-14, 1990. Walter de Gruyter, pp. 187-191, 1991.
43. Baumann, H., Brisson, J.-R., Michon, F. and Jennings, H.J. N.M.R. and conformational analysis of derivatives of -2,8-Sialyl oligosaccharides and comparison with the native compounds. **GLYCOCONJUGATE JOURNAL** 8, 126-127, 1991.
44. Bauman, H., Brisson, J.-R., Michon, F., Jennings, H.J., Tzianabos, A.O., and Kasper, D.L. Structural studies of two surface polysaccharides from the capsule of *Bacteroides fragilis* NCTC 9343. **GLYCOCONJUGATE JOURNAL** 8, 245-246, 1991.
45. Paoletti, L.C., Kasper, D.L., Michon, F., DiFabio, J., Jennings, H.J., Toaleson, T.D. and Wessels, M.R. Effects of chain length on the immunogenicity in rabbits of Group B *Streptococcus* type III oligosaccharide-tetanus toxoid conjugates. **JOURNAL OF CLINICAL INVESTIGATION** 83, 203-209, 1992.
46. Gamian, A., Beurret, M., Michon, F., Brisson, J.-R. and Jennings, H.J. Structure of the L2-lipopolysaccharide core oligosaccharide of *Neisseria meningitidis*. **JOURNAL OF BIOLOGICAL CHEMISTRY** 267, 912-925, 1992.
47. Paoletti, L.C., Wessels, M.R., Michon, F., DiFabio, J.L., Jennings, H.J., and Kasper, D.L. Group B *Streptococcus* type II polysaccharide-tetanus toxoid conjugate. **INFECTION AND IMMUNITY** 60, 4009-4014, 1992.
48. Paoletti, L.C., Wessels, M.R., Michon, F., Jennings, H.J. and Kasper, D.L. Group B *Streptococcus* type III glycoconjugate vaccines. **TRENDS IN GLYCOSCIENCE AND GLYCOTECHNOLOGY** 14, 269-278, 1992.
49. Chalifour, R.J., Michon, F., Jennings, H.J. and Lacroix, M. Use of defined oligosaccharide epitopes in an ELISA for Group B Streptococcal antigen. **JOURNAL OF IMMUNOLOGICAL METHODS** 154, 69-76, 1992.



50. Pavliak, V., Brisson, J.-R., Michon, F., Uhrin, D. and Jennings, H.J. Structure of the sialylated L3 Lipopolysaccharide of *Neisseria meningitidis*. **JOURNAL OF BIOLOGICAL CHEMISTRY** 268, 14146-14152, 1993.
51. Penney, C.L., Ethier, D., Dionne, G., Nixom-George, A., Zaghouani, H., Michon, F., Jennings, H.J. and Bona, C.A. Further studies on the adjuvanticity of stearyl tyrosine and ester analogues. **VACCINE** 11, 1129-1134, 1993.
52. Brisson, J.-R., Baumann, H., Michon, F., Pon, R. and Jennings, H.J. Comparison of the conformations of the (2,8)-linked sialic acid meningococcal polysaccharide with its reduced and N-acyl derivatives. **BIOCHEMISTRY** 32, 4000-4013, 1993.
53. Wessels, M.R., Paoletti, C.L., Rodewald, A.K., Michon, F., DiFabio, J., Jennings, H.J. and Kasper, D.L. Protective efficacy of type Ia polysaccharide-tetanus toxoid conjugate vaccine against experimental infection with *Group B Streptococcus* types Ia and Ib. **INFECTION AND IMMUNITY** 61, 4760-4766, 1993.
54. Jennings, H.J., Brisson, J.-R., Kulakowska, M. and Michon F. Polysialic acid vaccines against meningitis caused by *Neisseria meningitidis* and *Escherichia coli* K1. In Polysialic Acid (Roth, j. et al. eds), Birkhauser verlag, Switzerland, pp. 25-38, 1993.
55. Marques, M.B., Kasper, D.L., Shroff, A., Michon, F., Jennings, H.J., and Wessels, M.R., Functional activity of antibodies to the *Group B streptococcus* elicited by a polysaccharide-protein conjugate vaccine. **INFECTION AND IMMUNITY** 62, 1593-1599, 1994.
56. Laferriere, C.A., Sood, R.K., J.-M., De Muys, Michon, F., and Jennings, H.J. The synthesis of *Streptococcus pneumoniae* polysaccharide-tetanus toxoid conjugates and the effect of chain lenght on immunogenicity. **VACCINE** 15, 179-186, 1997.
57. D'Ambra, A.J., Concannon, P., Bauer, J., and Michon, F. A comparison of direct and indirect methods for the molar-mass analysis of fragments of the *Haemophilus influenzae* type b polysaccharide. **ANALYTICAL BIOCHEMISTRY**, 250, 1997.
58. Fusco, P.C., Michon, F., Blake, M.S., and Tai, J.Y. Preclinal evaluation of a Group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates. **JOURNAL OF INFECTIOUS DISEASES** 175, 364-372, 1997.
59. Bhasin, N., Albus, A., Michon, F., Livolsi, P., park, J.-S. and Lee, J.C. Identification of a gene essential for O-acetylation of the *Staphylococcus aureus* type 5 capsular polysaccharide. **MOLECULAR MICROBIOLOGY**, 27, 9-21, 1998.
60. Michon, F., Fusco, P.C., D'Ambra, A.J., Laude-Sharp, M., Long-Rowe, K., Blake, M.S., and Tai, J.Y. Combination conjugate vaccine against multiple serotypes of Group B streptococci. **Advances In Experimental Biology**. 847-850, 1997.
61. Fusco, P.C., Perry, J.W., Liang, S.-M, Blake, M.S., Michon, F., and Tai, J.Y. Bactericidal activity elicited by the beta C protein of Group B streptococci contrasted with capsular polysaccharides. **Advances In Experimental Biology**. 841-845, 1997.

62. Zabriskie, J.B., Poon-King, T., Blake, M.S., Michon, F., and Yoshinaga. Phagocytic, serological, and protective properties of streptococcal group A carbohydrate antibodies. **Advances Experimental Biology**. 917-919, 1997.
63. Wessels, M.R., Paoletti, L.C., Guttormsen, H.K., Michon, F., D'Ambra, A.J., and Kasper, D.L. Structural properties of group B Streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy. **INFECTION AND IMMUNITY**. 66, 2186-2192, 1998.
64. Laferriere, C.A., Sood, R.K., De Muys, J.-M., Michon, F., and Jennings, H.J. *Streptococcus pneumoniae* type 14 polysaccharide-conjugate vaccines: Length stabilization of opsonophagocytic conformational polysaccharide epitopes. **INFECTION AND IMMUNITY**. 66, 2441-2446, 1998.
65. Fusco, P.C., Blake, M.S., and Michon, F. Meningococcal Vaccine development: a novel approach. **EXPERT OPINION ON INVESTIGATIONAL NEW DRUGS**. 7, 245-252, 1998.
66. Fusco, P.C., Michon, F., Laude-Sharp, M., Minetti, C.A.S.A., Huang, C.-H., and Blake, M.S. Preclinical studies on a recombinant Group B meningococcal porin as a carrier for a novel *Haemophilus influenzae* type b conjugate vaccine. **VACCINE**. 16, 1842-1849, 1998.
67. Michon, F., Fusco, P.C., Minetti, C.A.S.A., Laude-Sharp, M., Uitz, C., Huang, C.-H., D'Ambra, A.J., Remeta, D., Heron, I., and Blake, M.S. Preclinical evaluation of a genetically detoxified Pneumolysin as a carrier for a multivalent pneumococcal polysaccharide conjugate vaccine. **VACCINE**. 16, 1732-1741, 1998.
68. Richmond, P., Goldblatt, D., Fusco, P.C., Fusco, J., Heron, I., Clark, S., Borrow, R., and Michon, F. Safety and immunogenicity of a new *Neisseria meningitidis* serogroup C tetanus toxoid conjugate vaccine in healthy adults. **VACCINE**. 18, 641-646, 1999.
69. Rubinstein, L.J., Garcia-Ojeda, P.A., Michon, F., Jennings, H.J., and Stein, K.E. Murine immune responses to *Neisseria meningitidis* group C capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine. **INFECTION AND IMMUNITY**. 66, 5450-5456, 1998.
70. Mackinnon, F.G., Ho, Y., Michon, F., Blake, M.S., Chandraker, A., Sayegh, M.H. and Wetzler, L.M. The role of B/T costimulatory signals in the immunopotentiating activity of neisserial porin. **JOURNAL OF INFECTIOUS DISEASES**, 180, 755-761, 1999.
71. Michon, F., Huang, C.-H., Farley, E.K., Hronowski, L., Di, J., and Fusco, P.C. Structure activities on group C meningococcal polysaccharide-protein conjugate vaccines: Effect of O-Acetylation on the nature of the protective epitope. **Dev Biol (Basel)**. 103, 151-160, 2000.

## ABSTRACTS / ORAL PRESENTATIONS (NAVA/BAXTER 1992-2003)

1. Pullen, J., Michon, F., de Muys, J.M., Huang, C., Hoskin, S., Jennings, H.J., and Tai, J.Y. 1992. Comparison of the immunogenicity of *Neisseria meningitidis* group C polysaccharide-protein conjugate vaccines. Abst 1288, 32<sup>nd</sup> ICAAC, New Orleans, LA.
2. Hronowski, L., Michon, F., Rohrbaugh, Prebula, R., Aggerbeck, H., Lin, W., Heron, I., Mates, and Tai, J.Y. 1993. Immunogenicity of a new *Haemophilus influenzae* Type b polysaccharide-tetanus toxoid (Hib-TT) conjugate vaccine and the immunogenicities of the individual Components in the pentavalent Hib-TT + DTaP + IPV Vaccine. Abst E-78 ASM 93<sup>rd</sup> general meeting, Atlanta, GA.
3. Hronowski, L., Di, J., Pullen, J., Rohrbaugh, J., Huang, C., Michon, F., and Tai, J.Y. 1993. Structure activity studies on *Neisseria meningitidis* Group C polysaccharide-protein conjugate vaccines. Abst E-75 ASM 93<sup>rd</sup> general meeting, Atlanta, GA.
4. Hronowski, L., Michon, F., Huang, C., Pullen, J., and Tai, J.Y. 1993. Development of a monovalent conjugate vaccine against *Neisseria meningitidis* group A and the divalent vaccine against groups A and C. Abst 174, 33<sup>rd</sup> ICAAC, New Orleans, LA.
5. Michon, F., Salvadori, L., Blake, M.S., Zabriskie, J.B., and Tai, J.Y. 1994. Candidate group A streptococcal conjugate vaccine based on the group A polysaccharide. Invited lecturer at the VI International Congress for Infectious diseases, Prague, Czech Republic.
6. Michon, F., Uitz, C., Concannon, P., and Tai, J.Y. 1994. Synthesis of modified sialic acids and their neolysyl amino-acid derivatives. XVII International Carbohydrate Symposium, Ottawa, Ontario, Canada.
7. Michon, F., D'Ambra, A.J., Uitz, C., Lhomar, P., Fusco, P.C., Enriquez, A., and Tai, J.Y. 1994. Further immunogenicity studies on conjugates of Types II and III capsular polysaccharides of group B streptococcus. ASM 94<sup>th</sup> General meeting, Las Vegas, NV.
8. Tai, J.Y., Michon, F., and Fusco, P.C. 1994. Development of conjugate vaccines against *Neisseria meningitidis*. Neisseria 94, Winchester, UK.
9. Fusco, P.C., Lhomar, P., Msays, R.M., Michon, F., and Tai, J.Y. 1994. Serological analyses from preclinical studies on meningococcal conjugate vaccines. Neisseria 94, Winchester, UK.
10. Tai, J.Y., Michon, F., and Fusco, P.C. 1995. Development of conjugate vaccines against *Neisseria meningitidis*. 19<sup>th</sup> ICAAC, Montreal, Canada.
11. Michon, F., Salvadori, L., Zabriskie, J.B., Blake, M.S., and Tai, J.Y. 1995. Candidate group A streptococcal conjugate vaccine based on the group A polysaccharide. 19<sup>th</sup> ICAAC, Montreal, Canada.
12. Michon, F., Uitz, C., Fusco, P.C., and Tai, J.Y. 1995. Group B streptococcus Type II and Type III neoglycoconjugate vaccines. Glyco XIII, Seattle, WA.
13. Tai, J.Y., Michon, F., Fusco, P.C. 1995. Antibody-dependent, Complement-mediated bactericidal activity elicited by group B meningococcal conjugate vaccines in mice and nonhuman primates. 35<sup>th</sup> ICAAC, San Francisco, CA.

14. Michon, F., Concannon, P., Huang, C.-H., and Tai, J.H. 1996 Analysis of meningococcal glycoconjugate vaccines by capillary electrophoresis. XVIII International Symposium, Milano, Italy, Abst. #AP077
15. Laferriere, G., Sood, R., De Muys, J.-M., Michon, F., and Jennings, H.J. 1996 Type 14 *S. pneumoniae* polysaccharide conjugate vaccines: effect of polysaccharide chain length on immunogenicity and opsonic activity of the corresponding antibody. XVIII International Symposium, Milano, Italy, ABST. # CO003.
16. Michon, F., Fusco, P.C., D'Ambra, A.J., Laude-Sharpe, M., Long-Rowe, K., Blake, M.S., and Tai, J.Y. 1996. Combination conjugate vaccine against multiple serotypes of Group B Streptococci. XIII Lancefield International Symposium on Streptococci and Streptococcal Diseases. Paris, France, Abstr. #P202.
17. Fusco, P., Perry, J.W., Liang, S.-M., Blake, M.S., Michon, F., and Tai, J.Y. 1996 Bactericidal activity elicited by the beta C protein of Group B Streptococci contrasted with capsular polysaccharides. XVIII Lancefield International Symposium on Streptococci and Streptococcal Diseases. Paris, France, Abst. # P201.
18. Zabriskie, J.B., Blake, M.S., Michon, F., and Yoshinaga, M. 1996. Phagocytic serological and protective properties of streptococcal Group A Carbohydrate antibodies. XVIII Lancefield International Symposium on Streptococci and Streptococcal Diseases. Paris, France, Abst. #P176.
19. Perry, J.W., Fusco, P.C., Michon, F., and Tai, J.Y. 1996. An opsonophagocytosis assay using HL-60 cells to measure potency of Group B streptococcal (GBS) and pneumococcal conjugate vaccines. 96<sup>th</sup> General Meeting of the American Society for Microbiology. New Orleans, Louisiana, Abst. # E-64.
20. Tai, J.Y., Michon, F., Fusco, P.C., and Blake, M.S. 1996. Preclinical evaluation of a combination vaccine against groups A,B, and C meningococci in both mice and nonhuman primates. Xth International Pathogenic Neisseria Conference, Baltimore, Maryland, 214-215.
21. Fusco, P.C., J.W. Perry, S.-M. Liang, M.S. Blake, F. Michon, and J.Y.Tai. 1997. Bactericidal Activity Elicited by the Beta C Protein of Group B Streptococci Contrasted with Capsular Polysaccharides. Adv. Exp. Med. Biol. 418: 841-845.
22. Michon, F., P.C. Fusco, A.J. D'Ambra, M. Laude-Sharp, K. Long-Rowe, M.S. Blake, and J.Y. Tai. 1997. Combination Conjugate Vaccines Against Multiple Serotypes of Group B Streptococci. Adv. Exp. Med. Biol. 418: 847-850.
23. Fusco, P.C., E.K. Farley, M.S. Blake, C.-H. Huang, J.Y. Tai, and F. Michon. 1997. Immunogenicity of Meningococcal Polysaccharide-Porin Conjugates in Nonhuman Primates. Abstract E6, 2<sup>nd</sup> National Symposium on Basic Aspects of Vaccines (Bethesda, MD., April30-May2,1997), Uniformed Services University of the Health Sciences/ Walter Reed Army Institute of Research/ U.S. Navy Medical Research and Development Command.
24. Fusco, P.C., M.S. Blake, C.-H. Huang, J.Y. Tai. and F. Michon. 1997. Preclinical Studies on a Novel Trivalent Meningococcal Conjugate Vaccine in Nonhuman Primates. Abstract E-70, p.252, American Society for Microbiology, 97<sup>th</sup> General Meeting (Miami Beach, FL., 1997), Washington, D.C.
25. Fusco, P.C., A.J. D'Ambra, C.-H. Huang, C. Uitz, S. Moore, J.W. Perry, J.Y. Tai, and F. Michon. 1997. Preclinical Studies in Mice on Combination Conjugate Vaccines against Pneumococcal Otitis Media.

Abstract E-63, p.251, American Society for Microbiology, 97<sup>th</sup> General Meeting (Miami Beach, FL., 1997) Washington, D.C.

26. Farley, E.K., P.C. Fusco, C.V. Badger, J.Y. Tai, and F. Michon. 1997. Characterization of Bactericidal Activity Elicited by a Novel Group B Meningococcal Polysaccharide/ Class 3 Porin Conjugate Vaccine in Nonhuman Primates. Abstract E-69, p.252, American Society for Microbiology, 97<sup>th</sup> General Meeting (Miami Beach, FL., 1997), Washington, D.C.
27. Laude-Sharp, M., P.C. Fusco, A.J. D'Ambra, K. Long-Powe, M.S. Blake, J.Y. Tai. And F. Michon. 1997. Preclinical Studies on Combination Conjugate Vaccines Against Multiple Serotypes of Group B Streptococci. Abstract E-62, p.251, American Society for Microbiology, 97<sup>th</sup> General Meeting (Miami Beach, FL, 1997) Washington, D.C.
28. Fusco, P.C., F. Michon, M. Laude-Sharp, C.A.S.A. Minetti, C.-H. Huang, and M.S. Blake. 1997. Preclinical Studies on Recombinant Group B Meningococcal Porin as a Carrier Protein for a Novel *Haemophilus influenzae* tybe B Conjugate Vaccine. Talk given at symposium of International Society for Vaccines, Leesburg, VA, 1997.
29. Moore, S. E.K. Farley, D.L. Hebblewaite, C.V. Badger, P.C. Fusco, I. Heron, and F. Michon. 1997. Specificity of Immune Response to the Modified Meningococcal B Polysaccharide/rPorB Conjugate Vaccine. Abstract G-2, p.192, American Society for Microbiology, 37<sup>th</sup> ICAAC (Toronto, Ontario, Canada, 1997), Washington, D.C.
30. Richmond, P.C., D. Goldblatt, P.C. Fusco, J.D.S. Fusco, I. Heron, and F. Michon, 1997. Phase I Evaluation of a Meningococcal C-Tetanus Toxoid Conjugate Vaccine. Abstract G-111, p.212, American Society for Microbiology, 37<sup>th</sup> ICAAC (Toronto, Ontario, Canada), Washington, D.C.
31. Fusco, P.C., J.W. Perry, M. Laude-Sharp, M.S. Blake, and F. Michon. 1998. Opsonophagocytic activity elicited by group B streptococcal polysaccharide-protein conjugates in preclinical studies. Invited talk at the CBER/NICH/NIAID GBS Workshop on Antibody Surrogates for Demonstration of Efficacy of a Group B Streptococcal Vaccine; Bethesda, MD.
32. Fusco, P.C., M.S. Blake, and F. Michon. 1998. Development of Group B Meningococcal Vaccine, Invited talk at the pre-congress session on meningococcal vaccines at the 16<sup>th</sup> Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID); Bled, Slovenia.
33. Richmond, P.C., D. Goldblatt, I. Heron, J.D.S Fusco, P.C. Fusco, and F. Michon. 1998. Quantitative and Qualitative Evaluation of a New Meningococcal C Conjugate Vaccine. Invited Talk presented by peter Richmond of UK group at the pre-congress session on meningococcal vaccines at the 16<sup>th</sup> Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID); Bled, Slovenia; May 27-29, 1998.
34. Fusco, P.C., C.A.S.A Minetti, M. Laude-Sharp, C. Uitz, C.-H. Huang, A.J. D'Ambra, M.S. Blake and F. Michon. 1998. Multivalent Pneumococcal Capsular Polysaccharide Conjugate Vaccines Employing Genetically Detoxified Pneumolysin as a Carrier protein. Poster presented by F. Michon at International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); Elsinor, Denmark; June 13-17, 1998.
35. Laude-Sharp, M., P.C. Fusco, C. Uitz, J.B. Rathmann, M.S. Walker, M.S. Blake, and F. Michon. 1998. Tetravalent Combination Conjugate Vaccines Against Group B Streptococci. Abstract G-59, p.301, American Society for Microbiology, 38<sup>th</sup> ICAAC (San Diego, California), Washington, D.C.



36. Fusco, P.C., F. Michon, M. Laude-Sharp, C.A.S.A. Minetti, C.-H. Huang, I. Heron, and M.S. Blake. 1998. Recombinant Group B Meningococcal Porin as a Carrier Protein for a Novel *Haemophilus influenzae* Type B Conjugate Vaccine. Abstract G-60, p.301, American Society for Microbiology, 38<sup>th</sup> ICAAC (San Diego, California, 1998), Washington, D.C.
37. Fusco, P.C., E.K. Farley, J. Bruge, B. Danve, N. Gibelin, M.S. Blake, F. Michon, and D. Schulz. 1998. Comparison of group B meningococcal conjugate vaccines in adult and infant rhesus monkeys: rPorB versus tetanus toxoid as protein carrier. 11<sup>th</sup> International Pathogenic Neisseria Conference, 1998
38. Fusco, P.C., E.K. Farley, M. Kristiansen, and F. Michon. 1999. Serologic Studies on Group C Meningococcal Vaccines. Presentation to World Health Organization for Position Paper: Standardization and validation of serologic assays for the evaluation of immune responses to *Neisseria meningitidis* serogroup A/C vaccines. WHO Headquarters, Geneva, March 8-9, 1999.
39. Fusco, P.C., E.K. Farley, I. Heron, M.S. Blake, and F. Michon. 1999. Clinical and preclinical studies on novel meningococcal conjugate vaccines. Society for Industrial Microbiology, 50<sup>th</sup> Anniversary Annual Meeting. Arlington, VA, August 1-5, 1999.
40. Fusco, P.C., J.W. Perry, and F. Michon. 1999. Antibody analysis in evaluation of pneumococcal conjugate vaccines. World Health Organization, Pan American Health Organization, and National Institutes of Health: Workshop on Standardization of Serologic Assays for the Evaluation of Immune Responses. Pan American Health Organization/WHO Regional Office for the Americas, Washington, D.C., August 31-September 2, 1999.
41. Fusco, P.C., E.K. Farley, M. Kristiansen, and F. Michon. 1999. Serologic Studies on Group C Meningococcal Vaccines. FDA/CBER: Vaccines and Related Biological Products Advisory Committee. Bethesda, MD, September 14-15, 1999.
42. Fusco, P.C., E.K. Farley, and F. Michon. 2000. Group B Meningococcal Polysaccharide-Protein Conjugate Vaccine. Presentation/consultation for World Health Organization meeting: Standardization and control of protein-based vaccines against serogroup B meningococcal disease. WHO Headquarters and Pan American Health Organization, Brazil, May 11-12, 2000.
43. Fusco, P.C., E.K. Farley, C.-H. Huang, M.S. Blake, and F. Michon. 2000. Preclinical studies on a Novel Trivalent Meningococcal Conjugate Vaccine for Serogroups B, C, and Y. Abstract E-49, p304, ASM 100<sup>th</sup> General Meeting, Los Angeles, CA.
44. Michon, F., C.-H. Huang, E.K. Farley, M.S. Blake, and P.C. Fusco. 2000. Novel Meningococcal Conjugate Vaccines. 9<sup>th</sup> International Congress on Infectious Diseases, Buenos Aires, Argentina, April 10-13.
45. Fusco, P.C., E.K. Farley, M.S. Blake, and F. Michon. 2001. Safety and Immunogenicity of a Group B Meningococcal Polysaccharide Conjugate Vaccine. 5<sup>th</sup> European Vaccine Manufacturers Conference. Lucerne, Switzerland, March, 2001.
46. Fusco, P.C., C.-H. Huang, E.K. Farley, and F. Michon. 2001. Effect of O-Acetylation on the Nature of the Protective Epitope and Serologic Correlates of Protection for the Group C Meningococcal Polysaccharide. Presentation/consultation for World Health Organization Expert Committee on Biological Standardization: Advisory Group Meeting for the Recommendations for the Production and Control of Serogroup C Meningococcal Conjugate Vaccines. WHO Headquarters, Geneva, October 4-5, 2001.



47. Fusco, P.C., E.K. Farley, M.S. Blake, and F. Michon. 2001. Meningococcal conjugate vaccines covering all major serogroups. 2<sup>nd</sup> European Society for Emerging Infections Congress. Budapest, Hungary, October 21-23, 2001.
48. Michon, F. C.-H. Huang, E.K. Farley, and P.C. Fusco. 2001. Structure Activity Studies on Group C Meningococcal Polysaccharide-Protein Conjugate Vaccines: Effect of O-Acetylation on the Nature of the Protective Epitope. CARB Abstract 24. American Chemical Society, 222<sup>nd</sup> National Meeting Chicago, IL, August, 2001.
49. Michon, F., M.S. Blake, and P.C. Fusco. 2001. Novel Meningococcal Semi-Synthetic Polysaccharide-Protein Conjugate Vaccines. BIOT Abstract 44. American Chemical Society, 221<sup>st</sup> National Meeting San Diego, CA, April 1-5, 2001.
50. Michon, F., C.-H. Huang, E.K. Farley, and P.C. Fusco. 2002. A Novel Conjugate Vaccine to Prevent Meningococcal C Disease. 85<sup>th</sup> Canadian Chemical Society Glycobiology Symposium, Vancouver, BC, Canada June 1-5, 2002.
51. Farley, E.K., C. Uitz, S. Moore, W. Dong and F. Michon. 2003. Effect of O- Acetylation of *Neisseria meningitidis* Serogroup Y Capsular Polysaccharide on Development of Functional antibodies. Abstract 3535, American Society for Microbiology, 43<sup>rd</sup> ICAAC, Chicago, Illinois, USA Sept 14-17.
52. Moore, S., C. Uitz, and F. Michon. 2003. Determinant Specificities of the Groups Y and W135 Meningococcal Polysaccharides. Evidence for Conformational epitopes. . Abstract 2453, American Society for Microbiology, 43<sup>rd</sup> ICAAC, Chicago, Illinois, USA Sept 14-17.
53. Farley, E.K., J. Saunders, D. Hebblewaite, K. Nauman, C. Uitz, S. Moore, C.H. Huang, K. Kim, K. Ren, P. Fusco, and F. Michon. 2003. Preclinical Studies on the Development of an Optimal Meningococcal CYW135 Conjugate Vaccine. Abstract 3405, American Society for Microbiology, 43<sup>rd</sup> ICAAC, Chicago, Illinois, USA Sept 14-17.
54. Kim, J., M. Kristiansen, M. Laude-sharp, C. Uitz, S. Moore, and F. Michon. 2003. Tetanus Toxin C Fragment as a Universal Carrier Protein for conjugate Vaccines. Abstract 2654, American Society for Microbiology, 43<sup>rd</sup> ICAAC, Chicago, Illinois, USA Sept 14-17.